• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Trending
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

synthetic lethality

Glowing puzzle piece fitting into puzzle
Biotech

Boehringer slots synthetic lethal program into oncology pipeline

Boehringer has partnered with Tessellate Bio on a synthetic lethal program in a deal worth more than 500 million euros in biobucks.
Nick Paul Taylor Apr 23, 2025 7:45am
team layoffs workforce

Zentalis lays off 40% to fund registrational trial of WEE1 drug

Jan 29, 2025 4:42am
pay deal hand over cash licensing transaction money

BeiGene inks $150M deal to follow cancer trail blazed by Amgen

Dec 13, 2024 9:11am
tango dance partner

Tango axes PRMT5 inhibitor, shifts focus to 2 sibling molecules

Nov 6, 2024 8:28am
Layoffs

Repare lays off 25% of staff as biotech halts preclinical R&D

Aug 29, 2024 6:36am
MA strategy deal block push come together form

Ideaya bags option on Biocytogen bispecific ADC in $400M deal

Jul 31, 2024 9:04am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings